Related Experiment Video
Updated: Mar 31, 2026

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
Published on: November 29, 2024
Glucagon Is a Safe and Inexpensive Initial Strategy in Esophageal Food Bolus Impaction
Jason Haas1,2, Julia Leo3, Nimish Vakil4,5,6
1Department of Gastroenterology, Aurora Health Care, 1218 W. Kilbourn Ave, Suite 404, Milwaukee, WI, 53233, USA. haas.jasonm@gmail.com.
Background:
Controversy exists about the utility of pharmacologic agents and endoscopic technique used for esophageal food bolus impaction.
Aim:
To evaluate the utility of glucagon and the technique used for endoscopic removal, including the rate of success and the adverse events of the techniques.
Methods:
The database of the largest healthcare provider in southeastern Wisconsin was retrospectively reviewed for patients presenting with esophageal food bolus impaction. Data extracted included glucagon administration and its success rate, outcome of radiographic studies, and the endoscopic method of removal and adverse events associated with it, including 30-day mortality.
Results:
A total of 750 patients were identified with food bolus impaction from 2007 to 2012. Glucagon was administered in 440 patients and was successful in 174 (39.5%). Endoscopic removal was performed in 470 patients and was successful in 469 (99.8%). The push technique was utilized in 209 patients, reduction in the bolus size by piecemeal removal followed by the push technique was utilized in 97 patients, and the pull technique was utilized in 107 patients. There were no perforations with endoscopic removal. Only 4.5% of the X-rays performed reported a possible foreign body within the esophagus. Glucagon was a significantly less-expensive strategy than endoscopic therapy (p < 0.0001).
Conclusion:
Glucagon is low cost, is moderately effective, and may be considered as an initial strategy. Endoscopic removal regardless of technique is safe and effective. The yield of radiography is poor in the setting of food bolus impaction.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Hypoglycemia and Glucagon
Oral Hypoglycemic Agents: Glinides
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Barrett Esophagus-II: Clinical Manifestations and Management
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
Deglutition
Swallowing can be divided into three stages: the voluntary phase, the pharyngeal phase, and the esophageal phase. Although the...

